Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

BostonGene

Explore full profile

Biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer

Waltham, United StatesFounded 2015Health Tech & Medtech
Valuation $1–2.5B Last recorded · 2022
Headcount 100–500 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for BostonGene and the history behind them.

About BostonGene

BostonGene is a pioneering company in the field of precision medicine, focusing on personalized cancer treatment. The company collaborates with leading cancer centers to provide innovative technologies that enhance patient outcomes. Utilizing a cloud-based platform, BostonGene integrates AI-driven molecular and immune profiling techniques to analyze tumors, the microenvironment, and host immunity comprehensively. This approach allows for the creation of a vast and continually updated database of biomarkers, therapies, clinical trials, and therapeutic guidelines. The company's business model revolves around offering these advanced diagnostic and analytical tools to healthcare providers, enabling them to devise the most effective personalized treatment strategies for their patients. BostonGene serves a diverse range of clients, including cancer centers, hospitals, and medical professionals, primarily operating in the healthcare and biotechnology markets. Revenue is generated through the sale of its cloud-based software platform, bioinformatics capabilities, and next-generation sequencing (NGS) services. The company also offers a Financial Assistance Program for qualified patients who prefer not to use insurance or are not covered.

Source: Dealroom company data

At a glance

Founded
2015
Headquarters
Waltham, United States
Sector
Health Tech & Medtech
Power Law
Unicorn$1–10B valuation tier

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Nec
  • Japan Industrial Partners
  • Impact Investment Capital

Series B and later2 investors entered at this stage

  • Impact Investment Capital
  • Japan Industrial Partners
Employees mapped 373 incl. 7 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
15 countries with
team presence
🇦🇲 Armenia57.7%
🇺🇸 United States27.1%
🇷🇺 Russia5.2%
🇨🇴 Colombia4.2%
🇩🇪 Germany1.6%
Top 5 of 15 shown
Web traffic by country
12K monthly visits
across markets
🇺🇸 United States62.5%
🇦🇲 Armenia18.3%
🏳️ Russian Federation6.7%
🇮🇳 India4.2%
🇩🇪 Germany4.2%
Top 5 markets shown

Patents

Estimated portfolio value
$91M

52 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about BostonGene on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See BostonGene on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.